hotspot -WSS

hotspot

author：fashion 2025-09-28 18:30:45 - browse：7

Two researchers look at a projection screen displaying medical devices, scientific graphs and DNA — health tech coverage from STAT — Adobe

The federal government’s plan to boost its oversight of the use of artificial intelligence tools in health care drew censure from startups arguing that overregulation stifles new ideas. But as Washington forges ahead, founders say they’re in the dark about who will be regulated and how — and they’re urging policymakers to offer clarity.

As they race for a slice of the $4 trillion U.S. health care market, AI founders and investors say regulatory uncertainty is a hurdle, forcing them to build more slowly and meticulously document for fear of potential audits. That makes it harder to keep up with the tech industry’s breakneck pace, they tell STAT.

The regulatory uncertainty adds to the many challenges dogging young health tech ventures today: Last year investments in digital health startups shriveled to their lowest annual total since 2019, and leaders are desperate to preserve what little funds they have, including through layoffs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Chemotherapy shortages won’t get better under Biden’s latest plan

explore

WSS

Readout LOUD: Venture capital, Gilead, and more M&A

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Adopting new red light myopia treatments may be short

Why Novartis is going to walk from its acquisition of MorphoSys

Top private equity targets in 2023: cardiology, clinical trials, lasers

What PEPFAR has meant on the ground in Ukraine

entertainment

hotspot

explore

Medical leaders decry Supreme Court decision on affirmative action

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Novavax promises a turnaround & Lilly roils the obesity market

Supreme Court wrestles with OxyContin maker's bankruptcy deal

At least 13 dead in Texas as scorching temps continue

Medicare Advantage plans can’t deny care with AI, CMS warns

Peter Hotez and the public health issue of online harassment

SCOTUS to consider access to abortion pill mifepristone

DIEP, the 'gold standard' of breast reconstruction, is under threat

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Wikipedia

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

AI models in health care face new federal disclosure requirements

The CDC's new social media misinformation war

SCOTUS to consider access to abortion pill mifepristone

AI gets buy

entertainment

focus

explore

leisure time